MONTE ROSA THERAPEUTICS INC (GLUE) Stock Earnings & Estimates
NASDAQ:GLUE - US61225M1027 - Common Stock
4.8 USD
-0.03 (-0.62%)
4.9 USD
+0.1 (+2.08%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 75.622M | 138.96M 83.76% | 51.391M -63.02% | 62.249M 21.13% | 45.749M -26.51% | 72.589M 58.67% | 197.53M 172.12% | 563.86M 185.46% | 859.08M 52.36% | |||
| EBITDA YoY % growth | -108.63M -53.54% | -137.089M -26.20% | -72.991M 46.76% | -56.1M 23.14% | -25.5M 54.55% | -88.75M -248.04% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -112.38M -54.20% | -143.311M -27.52% | -81.112M 43.40% | -58.686M 27.65% | -137.288M -133.94% | -144.449M -5.22% | -163.273M -13.03% | -171.942M -5.31% | -91.926M 46.54% | 121.18M 231.82% | 222.46M 83.58% | |
| Operating Margin | N/A | N/A | -107.26% | -42.23% | -267.14% | -232.05% | -356.89% | -236.87% | -46.54% | 21.49% | 25.90% | |
| EPS YoY % growth | -2.29 20.50% | -2.64 -15.28% | -1.02 61.36% | -0.22 78.74% | -1.43 -560.62% | -1.33 6.82% | -1.43 -7.45% | -1.41 1.85% | -0.57 59.86% | 1.40 347.29% | 2.39 70.80% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.35 -20.42% | -0.25 -206.88% | -0.49 -187.43% | -0.52 -246.80% | -0.55 -57.72% | -0.59 -138.59% |
| Revenue Q2Q % growth | 9.834M 6.71% | 18.887M -68.86% | 1.36M -98.40% | 1.36M -94.14% | 680.003K -93.09% | 680.003K -96.40% |
| EBITDA Q2Q % growth | -23.904M -16.79% | -5.59M -126.46% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -30.8M -16.11% | -22.665M -274.29% | -42.84M -197.28% | -45.39M -191.82% | -47.43M -53.99% | -49.98M -120.51% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -0.15 65.12% | -0.39 | 0.24 | 61.87% |
| Q1 2025 Q2Q % growth | 0.56 205.66% | -0.34 | 0.90 | 262.91% |
| Q4 2024 Q2Q % growth | 0.23 139.66% | -0.02 | 0.25 | 1,080.39% |
| Q3 2024 Q2Q % growth | -0.29 58.57% | -0.50 | 0.21 | 41.55% |
| Q2 2024 Q2Q % growth | -0.43 39.44% | -0.55 | 0.12 | 21.93% |
| Q1 2024 Q2Q % growth | -0.53 18.46% | -0.58 | 0.05 | 9.30% |
| Q4 2023 Q2Q % growth | -0.58 7.94% | -0.34 | -0.24 | -69.89% |
| Q3 2023 Q2Q % growth | -0.70 -20.69% | -0.74 | 0.04 | 5.18% |
| Q2 2023 Q2Q % growth | -0.71 -24.56% | -0.71 | 0.00 | 0.56% |
| Q1 2023 Q2Q % growth | -0.65 -27.45% | -0.69 | 0.04 | 6.17% |
| Q4 2022 Q2Q % growth | -0.63 32.26% | -0.64 | 0.01 | 0.95% |
| Q3 2022 Q2Q % growth | -0.58 -34.88% | -0.61 | 0.03 | 5.21% |
| Q2 2022 Q2Q % growth | -0.57 84.30% | -0.55 | -0.02 | -3.39% |
| Q1 2022 Q2Q % growth | -0.51 | -0.53 | 0.02 | 4.21% |
| Q4 2021 Q2Q % growth | -0.93 | -0.51 | -0.42 | -82.96% |
| Q3 2021 Q2Q % growth | -0.43 | -0.45 | 0.02 | 4.62% |
| Q2 2021 Q2Q % growth | -3.63 | -0.41 | -3.22 | -784.18% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | 23.194M 394.01% | 11.016M | 12.178M | 110.55% |
| Q1 2025 Q2Q % growth | 84.929M 7,882.05% | 15.586M | 69.343M | 444.91% |
| Q4 2024 Q2Q % growth | 60.647M | 11.611M | 49.036M | 422.32% |
| Q3 2024 Q2Q % growth | 9.216M | 2.673M | 6.543M | 244.78% |
| Q2 2024 Q2Q % growth | 4.695M | 1.376M | 3.319M | 241.21% |
| Q1 2024 Q2Q % growth | 1.064M | 1.428M | -364K | -25.49% |
| Q4 2023 Q2Q % growth | 15.453M | -15.453M | -100.00% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 11.89% | 10.29% | 62.23% | 82.96% |
| Revenue | -8.31% | 478.47% | 23.31% | 105.64% |